Literature DB >> 23456611

Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine.

Yoko S DeRose1, Keith M Gligorich, Guoying Wang, Ann Georgelas, Paulette Bowman, Samir J Courdy, Alana L Welm, Bryan E Welm.   

Abstract

Research models that replicate the diverse genetic and molecular landscape of breast cancer are critical for developing the next-generation therapeutic entities that can target specific cancer subtypes. Patient-derived tumorgrafts, generated by transplanting primary human tumor samples into immune-compromised mice, are a valuable method to model the clinical diversity of breast cancer in mice, and are a potential resource in personalized medicine. Primary tumorgrafts also enable in vivo testing of therapeutics and make possible the use of patient cancer tissue for in vitro screens. Described in this unit are a variety of protocols including tissue collection, biospecimen tracking, tissue processing, transplantation, and three-dimensional culturing of xenografted tissue, which enable use of bona fide uncultured human tissue in designing and validating cancer therapies. Curr. Protoc. Pharmacol. 60:14.23.1-14.23.43.
© 2013 by John Wiley & Sons, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23456611      PMCID: PMC3630511          DOI: 10.1002/0471141755.ph1423s60

Source DB:  PubMed          Journal:  Curr Protoc Pharmacol        ISSN: 1934-8282


  19 in total

1.  Mammary cancer produced in mice with estriol.

Authors:  G Rudali; F Apiou; B Muel
Journal:  Eur J Cancer       Date:  1975-01       Impact factor: 9.162

2.  Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer.

Authors:  Bryan E Welm; Gerrit J P Dijkgraaf; Anita S Bledau; Alana L Welm; Zena Werb
Journal:  Cell Stem Cell       Date:  2008-01-10       Impact factor: 24.633

Review 3.  Mouse models in oncogenesis and cancer therapy.

Authors:  M V Céspedes; I Casanova; M Parreño; R Mangues
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405

4.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Authors:  Richard M Neve; Koei Chin; Jane Fridlyand; Jennifer Yeh; Frederick L Baehner; Tea Fevr; Laura Clark; Nora Bayani; Jean-Philippe Coppe; Frances Tong; Terry Speed; Paul T Spellman; Sandy DeVries; Anna Lapuk; Nick J Wang; Wen-Lin Kuo; Jackie L Stilwell; Daniel Pinkel; Donna G Albertson; Frederic M Waldman; Frank McCormick; Robert B Dickson; Michael D Johnson; Marc Lippman; Stephen Ethier; Adi Gazdar; Joe W Gray
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

5.  Optimization of 25 kDa linear polyethylenimine for efficient gene delivery.

Authors:  Sun-Hyung Huh; Hyun-Jin Do; Hye-Young Lim; Dong-Ku Kim; Seong-Jun Choi; Hyuk Song; Nam-Hyung Kim; Jin-Ki Park; Won-Kyong Chang; Hyung-Min Chung; Jae-Hwan Kim
Journal:  Biologicals       Date:  2006-11-01       Impact factor: 1.856

Review 6.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.

Authors:  Theodora Voskoglou-Nomikos; Joseph L Pater; Lesley Seymour
Journal:  Clin Cancer Res       Date:  2003-09-15       Impact factor: 12.531

Review 7.  Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.

Authors:  Robert S Kerbel
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

Review 8.  Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines.

Authors:  R Clarke
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

9.  Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines.

Authors:  Patrica J Keller; Amy F Lin; Lisa M Arendt; Ina Klebba; Ainsely D Jones; Jenny A Rudnick; Theresa A DiMeo; Hannah Gilmore; Douglas M Jefferson; Roger A Graham; Stephen P Naber; Stuart Schnitt; Charlotte Kuperwasser
Journal:  Breast Cancer Res       Date:  2010-10-21       Impact factor: 6.466

Review 10.  Breast cancer cell lines: friend or foe?

Authors:  Sarah E Burdall; Andrew M Hanby; Mark R J Lansdown; Valerie Speirs
Journal:  Breast Cancer Res       Date:  2003-02-03       Impact factor: 6.466

View more
  90 in total

1.  Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo.

Authors:  Jason J Zoeller; Aleksandr Vagodny; Krishan Taneja; Benjamin Y Tan; Neil O'Brien; Dennis J Slamon; Deepak Sampath; Joel D Leverson; Roderick T Bronson; Deborah A Dillon; Joan S Brugge
Journal:  Mol Cancer Ther       Date:  2019-04-08       Impact factor: 6.261

2.  Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing.

Authors:  Samantha M Sarett; Thomas A Werfel; Linus Lee; Meredith A Jackson; Kameron V Kilchrist; Dana Brantley-Sieders; Craig L Duvall
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

3.  Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Authors:  Svasti Haricharan; Nindo Punturi; Purba Singh; Kimberly R Holloway; Meenakshi Anurag; Jacob Schmelz; Cheryl Schmidt; Jonathan T Lei; Vera Suman; Kelly Hunt; John A Olson; Jeremy Hoog; Shunqiang Li; Shixia Huang; Dean P Edwards; Shyam M Kavuri; Matthew N Bainbridge; Cynthia X Ma; Matthew J Ellis
Journal:  Cancer Discov       Date:  2017-08-11       Impact factor: 39.397

4.  Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies.

Authors:  Colton Hanna; Letty Kwok; Jessica Finlay-Schultz; Carol A Sartorius; Diana M Cittelly
Journal:  J Vis Exp       Date:  2016-11-30       Impact factor: 1.355

5.  Detection and Elimination of Corynebacterium bovis from Barrier Rooms by Using an Environmental Sampling Surveillance Program.

Authors:  Christopher A Manuel; Umarani Pugazhenthi; Shannon P Spiegel; Jori K Leszczynski
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-03-01       Impact factor: 1.232

6.  Procedure for Horizontal Transfer of Patient-Derived Xenograft Tumors to Eliminate Corynebacterium bovis.

Authors:  Christopher A Manuel; Stacey M Bagby; Julie A Reisinger; Umarani Pugazhenthi; Todd M Pitts; Stephen B Keysar; John J Arcaroli; Jori K Leszczynski
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-03-01       Impact factor: 1.232

7.  Methylparaben stimulates tumor initiating cells in ER+ breast cancer models.

Authors:  M Angeles Lillo; Cydney Nichols; Chanel Perry; Stephanie Runke; Raisa Krutilina; Tiffany N Seagroves; Gustavo A Miranda-Carboni; Susan A Krum
Journal:  J Appl Toxicol       Date:  2016-09-01       Impact factor: 3.446

Review 8.  The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer.

Authors:  Britta Weigelt; Cyrus M Ghajar; Mina J Bissell
Journal:  Adv Drug Deliv Rev       Date:  2014-01-09       Impact factor: 15.470

9.  A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.

Authors:  Margarite D Matossian; Hope E Burks; Annie C Bowles; Steven Elliott; Van T Hoang; Rachel A Sabol; Nicholas C Pashos; Benjamen O'Donnell; Kristin S Miller; Bahia M Wahba; Bruce A Bunnell; Krzysztof Moroz; Arnold H Zea; Steven D Jones; Augusto C Ochoa; Amir A Al-Khami; Fokhrul Hossain; Adam I Riker; Lyndsay V Rhodes; Elizabeth C Martin; Lucio Miele; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Breast Cancer Res Treat       Date:  2018-02-01       Impact factor: 4.872

10.  Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.

Authors:  Magdalena Bieniasz; Parvathi Radhakrishnan; Najme Faham; Jean-Paul De La O; Alana L Welm
Journal:  Clin Cancer Res       Date:  2015-08-19       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.